Publication | Closed Access

Luxturna: FDA documents reveal the value of a costly gene therapy

Gene TherapiesNovel TherapyIn Vivo Gene TherapyGeneticsPharmacologyGenetic EngineeringFda DocumentsPharmacogenomicsPharmacotherapyCostly Gene TherapyTherapeutic PatentMedicineGenome Editing